Mortality rate and outcome factors in mixed cryoglobulinaemia: The impact of hepatitis C virus

Scandinavian Journal of Rheumatology

Volumn 39, Issue 2, 2010, Pages 167-170

  Rossa, A Della ^a   Tavoni, A ^a   D'Ascanio, A ^a   Catarsi, E ^a   Marchi, F ^a   Bencivelli, W ^a   Salvadori, S ^b   Migliorini, P ^a   Bombardieri, S ^a  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; RECOMBINANT INTERFERON; RIBAVIRIN; RITUXIMAB;

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC VASCULITIS;

CAUSE OF DEATH; CRYOGLOBULINEMIA; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 77950194509     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740903313639     Document Type: Article

References (15)

1. Della Rossa A, Ferri C, Bombardieri SFrom essential mixed cryoglobulinemia to virus induced autoimmnunity: ten years of research in mixed cryoglobulinemia. In: Shoenfeld Y, editor. The decaDe of autoimmunity. Amsterdam: Elsevier Sciences, 1999:235-243
2. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991;9:621-624
3. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42:2204-2212
4. Bombardieri S, Della Rossa A. HowHCVinfection has changed the clinical approach to mixed cryoglobulinemia. Ann Rheum Dis 2007;66(Suppl 2):45.
5. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67:283-287
6. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longobardo G, Antonelli A, et al. Mixed cryoglobulinemia: demographic, clinical and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-374
7. Mascia MT, Ferrari D, Campioli D, Sandri G, Mussini C, Ferri C. Non HCV-related mixed cryoglobulinemia. Dig Liver Dis 2007; 39(Suppl 1):S61-4.
8. Ramos-Casals M, Robles A, Brito-Zeron P, Nardi N, Nicolas MJ, Forns X, et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006;36:189-196
9. Kallemuchikkal U, Gorevich PD. Evaluation of cryoglobulins. Arch Pathol Lab Med 1999;123:119-125
10. Wasiuddin AK, Delbert RV, Michael MFComplement and chinins mediators of inflammation. In: Henry JB, editor. Clinical diagnosis and management by laboratory methods, 19th edn. Philadelphia: WB Saunders, 1996:928-946
11. Erensoy S. Diagnosis of hepatitis C virus (HCV) infection and laboratory monitoring of its therapy. J Clin Virol 2001;21:271-281
12. Marchi F, Della Rossa A, Tavoni A, Baldini C, d'Ascanio A, Bombardieri S, et al. Efficacy and safety of rituximab in mixed cryoglobulinemia patients. Ann Rheum Dis 2007.
13. Available online at: www.iss.it/site/mortalita/Scripts/SelCause.asp.
14. Bedogni G, Miglioli L, Masutti F, Ferri S, Castiglione A, Lenzi M, et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dyonisos study. Am J Gastroenterol 2008;2103:2248-2253
15. Della Rossa A, Marchi F, Catarsi E, Tavoni A, Bombardieri S. Mortality in mixed cryoglobulinemia: a review of the literature. Clin Exp Rheumatol 2008;26(Suppl 51):S105-8.